[go: up one dir, main page]

TN2011000009A1 - Pyridazne derivatives as smo inhibitors - Google Patents

Pyridazne derivatives as smo inhibitors

Info

Publication number
TN2011000009A1
TN2011000009A1 TN2011000009A TN2011000009A TN2011000009A1 TN 2011000009 A1 TN2011000009 A1 TN 2011000009A1 TN 2011000009 A TN2011000009 A TN 2011000009A TN 2011000009 A TN2011000009 A TN 2011000009A TN 2011000009 A1 TN2011000009 A1 TN 2011000009A1
Authority
TN
Tunisia
Prior art keywords
methods
agents
pyridazne
derivatives
tumor
Prior art date
Application number
TN2011000009A
Other languages
French (fr)
Inventor
Naeem Yusuff
Zhuoliang Chen
Bharat Lagu
Feng He
Stfan Peukert
Moslin Karen Miller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/059138 external-priority patent/WO2010007120A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2011000009A1 publication Critical patent/TN2011000009A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action involve methods of inhibiting tumorigenesis, tumor growth and tumor survival using agents that inhibit the Hedgehog and Smo signaling pathway.
TN2011000009A 2009-07-16 2011-01-07 Pyridazne derivatives as smo inhibitors TN2011000009A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/059138 WO2010007120A1 (en) 2008-07-18 2009-07-16 Pyridazine derivatives as smo inhibitors

Publications (1)

Publication Number Publication Date
TN2011000009A1 true TN2011000009A1 (en) 2012-09-05

Family

ID=55024324

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000009A TN2011000009A1 (en) 2009-07-16 2011-01-07 Pyridazne derivatives as smo inhibitors

Country Status (1)

Country Link
TN (1) TN2011000009A1 (en)

Similar Documents

Publication Publication Date Title
MY149716A (en) Pyridazine derivatives as smo inhibitors
IN2012DN02081A (en)
UA100684C2 (en) Normal;heading 1;heading 2;heading 3;BENZYL AND PYRIDINYL DERIVATIVES AS MODULATORS OF THE HEDGEHOG SIGNALING PATHWAY
MY165579A (en) Synthetic methods for spiro-oxindole compounds
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MX2020012825A (en) Multicyclic compounds and methods of use thereof.
PH12012501768A1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
UA117830C2 (en) Bipyrazole derivatives as jak inhibitors
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX2013012652A (en) Derivatives of n- [(1h-pyrazol-1-yl) aryl] - 1h - indole or 1h - indazole - 3 - carboxamide, their preparation and their use as p2y12 antagonists.
MX2014000964A (en) Substituted heterocyclic aza derivatives.
MX2012006822A (en) 1, 7 - diazacarbazoles and their use in the treatment of cancer.
MX2012001413A (en) Novel azaheterocyclic compounds.
MX2011008195A (en) Indole derivatives as anticancer agents.
MX2013002155A (en) Compounds for treatment of cancer.
SA515360377B1 (en) Somatostatin-dopamine chimeric analogs
MX2014003584A (en) Substituted methanesulfonamide derivatives as vanilloid receptor ligands.
MX2014003455A (en) Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands.
IN2014KN00849A (en)
TN2011000009A1 (en) Pyridazne derivatives as smo inhibitors
MA33958B1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders